Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ASLAN Pharmaceuticals Ltd (ASLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 6-K Quarterly results
Docs: "6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab, a potential first-in-class antibody, as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation - Data supports advancement of eblasakimab into Phase 3 clinical development program in 2024 - Readouts from TREK-DX Phase 2 study of eblasakimab and FAST-AA Phase 2a study of farudodstat both expected in the first quarter of 2024 - Company maintains healthy operating position with $40.9 million in cash and ca..."
07/20/2023 6-K Quarterly results
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Opinion of Walkers (Singapore) Limited Liability Partnership, Cayman Islands counsel to the Company",
"Opinion of Walkers (Singapore) Limited Liability Partnership, Cayman Islands counsel to the Company"
07/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"EBLASAKIMAB MONTHLY DOSING SHOWS POTENTIAL FOR BEST-IN-CLASS THERAPY IN POSITIVE PHASE 2B STUDY IN ATOPIC DERMATITIS - Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. - 600mg eblasakimab dosed once every four weeks in the TREK-AD study met the primary endpoint with statistical significance, with 62.7% of patients achieving EASI-75, 34.1% reaching EASI-90 and 31.2% achieving vIGA-AD of 0 or 1. - Regimens dosing once every two weeks also met the primary endpoint with statistical significance, as well as meeting key secondary endpoints. - Unique loading dose regimen observed to deliver rapid onset of action with..."
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Amendment No. 1 to Warrant to Purchase Ordinary Shares",
"First Amendment to Loan, Guaranty and Security Agreement, by and among ASLAN Pharmaceuticals Limited, ASLAN Pharmaceuticals (USA) Inc., ASLAN Pharmaceuticals Ptd. Ltd., and K2 HealthVentures LLC"
04/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE"
03/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE"
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE San Mateo, California, and Singapore, March 10, 2023 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it plans to change the ratio of the American Depositary Shares to its ordinary shares, par value $0.01 per share, from one ADS representing five ordinary shares to one ADS representing twenty-five ordinary shares. For the Company’s existing ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split. There will be no change to the Company’s ordinary shares. The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected t..."
02/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Unit Purchase Agreement dated February 24, 2023, by and among ASLAN Pharmaceuticals Limited and the Purchasers named therein",
"Form of Pre-Funded Warrant",
"Form of Tranche 1A Warrant",
"Form of Tranche 1B Warrant",
"Form of Tranche 2A Warrant",
"Form of Tranche 2B Warrant"
01/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Companies Act")."
01/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS AND THERMO FISHER SCIENTIFIC ANNOUNCE PARTNERSHIP TO MANUFACTURE HIGH CONCENTRATION FORMULATION OF EBLASAKIMAB FOR FUTURE STUDIES - Thermo Fisher Scientific to provide biologic manufacturing expertise and scale-up capacity to manage the clinical supply of eblasakimab for future Phase 3 studies - A high concentration formulation of eblasakimab will be manufactured which could enable doses of up to 400mg eblasakimab to be delivered via a single subcutaneous injection San Mateo, California, and Singapore, January 3, 2023 –"
12/21/2022 6-K Quarterly results
10/28/2022 6-K Quarterly results
09/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"PRESS RELEASE ASLAN PHARMACEUTICALS COMMENCES CLINICAL PROGRAM TO STUDY EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS -"
09/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"SCHEDULE 1 LIST OF DOCUMENTS EXAMINED 1. The Certificate of Incorporation dated 23 June 2014, the Tenth Amended and Restated Memorandum and Articles of Association as adopted on 16 November 2020 by special resolution passed on 4 September 2020 , Register of Members and Register of Directors, in each case, of the Company, copies of which have been provided to us by its registered office in the Cayman Islands and/or the Company's advisers . 2. A copy of a Certificate of Good Standing dated 9 September 2022 in respect of the Company issued by the Registrar . 3. Copies of executed minutes of meetings of the Board of Directors of the Company dated, respectively, 10 September 2018, 7 November 2018, 6 January 2019, 26 April 2019, 13 May 2019, 30 September 2019, 4 October 2019, 17 July 2020 and 7 ...",
"AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM"
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS PRESENTS NEW DATA ON EBLASAKIMAB IN MULTIPLE POSTERS AT THE 31st ANNUAL EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY CONGRESS • Data presented at EADV for the first time show eblasakimab suppresses downstream inflammatory biomarkers of atopic dermatitis, continuing 4-6 weeks after the last dose • Notable improvements in quality-of-sleep measures, with fewer patients reporting sleep disturbance on eblasakimab • Eblasakimab significantly reduced P-NRS scores and improvements continued throughout 8-week course of treatment across all dose cohorts California and Singapore, September 7, 2022 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, to..."
08/12/2022 6-K Quarterly results
Docs: "FORM 6-K",
"ASLAN PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE",
"ASLAN Pharmaceuticals Limited Financial Statements for the six months ended June 30, 2022"
04/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis progressing, multiple sites enrolling; topline data expected in the first half of 2023 - Alex Kaoukhov, MD, appointed as Chief Medical Officer, adding global pharma leadership experience ahead of advancing eblasakimab to later stage development and prioritizing additional programs and indications - Company maintains healthy operating position with US$87.4 million in cash, cash equivalents and short-term investments as of March 31, 2022, runway through late 2023 Menlo Park, California, and Singapore, April 27, 2022 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fi..."
04/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN PHARMACEUTICALS ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY NOTICE REGARDING MINIMUM BID PRICE"
03/25/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis underway with topline data expected in the first half of 2023 - New CMO appointed, adding senior global pharma experience to the leadership team - Company maintains strong operating position with US$90.2 million in cash and cash equivalents as of December 31, 2021, runway through late 2023 - Replays available for company-hosted A4 KOL series on AD landscape; next event to be held in the second quarter Menlo Park, California, and Singapore, March 25, 2022 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provi..."
03/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis - Strengthens leadership team as eblasakimab moves into late-stage trials Menlo Park, California, and Singapore, March 15, 2022 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately. Alex was most recently Head of Clinical Development, Senior Vice President at Bioniz Therapeutics where he established and managed a team responsible for the development of therapeutic assets for the treatment of skin and gastroin..."
01/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 430-7577 Email: [email protected] About ASLAN Pharmaceuticals ASLAN Pharmaceuticals is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn. About eblasakimab Eblasakimab, also known as ASLAN004, is a novel, first-in-class monoclonal antibody that targets the IL-13 receptor α1 subun..."
10/26/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose trial in patients with moderate-to-severe atopic dermatitis - On track to initiate Phase 2b 300-patient clinical trial for ASLAN004 in 4Q 2021 - Company maintains strong operating position and cash runway through late 2023 - Replay available for company-hosted KOL event on AD landscape and to recap Phase 1 MAD data Menlo Park, California, and Singapore, 26 October 2021 – ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2021, and provided an update on recent corporate activities."
09/27/2021 6-K Quarterly results
08/06/2021 6-K Quarterly results
07/14/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Warrant to Purchase Ordinary Shares",
"Loan, Guaranty, and Security Agreement, by and among ASLAN Pharmaceuticals Limited, ASLAN Pharmaceuticals (USA) Inc., ASLAN Pharmaceuticals Pte. Ltd, K2 HealthVentures LLC and Ankura Trust Company, LLC"
05/11/2021 6-K Quarterly results
04/22/2021 6-K Quarterly results
03/18/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/04/2021 6-K Quarterly results
03/01/2021 6-K Quarterly results
03/01/2021 6-K Quarterly results
02/25/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy